S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The Next Big Crisis Is Here (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Is This The End of Capitalism? (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The Next Big Crisis Is Here (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Is This The End of Capitalism? (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The Next Big Crisis Is Here (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Is This The End of Capitalism? (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The Next Big Crisis Is Here (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Is This The End of Capitalism? (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
NASDAQ:ALKS

Alkermes - ALKS Stock Forecast, Price & News

$28.50
+0.16 (+0.56%)
(As of 01/26/2023 12:00 AM ET)
Add
Compare
Today's Range
$28.16
$28.55
50-Day Range
$23.44
$28.54
52-Week Range
$21.75
$32.79
Volume
1.04 million shs
Average Volume
1.54 million shs
Market Capitalization
$4.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.10

Alkermes MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
4.9% Upside
$29.89 Price Target
Short Interest
Bearish
5.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.22
Upright™ Environmental Score
News Sentiment
0.30mentions of Alkermes in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.29) to ($0.21) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

Medical Sector

970th out of 1,048 stocks

Pharmaceutical Preparations Industry

471st out of 513 stocks


ALKS stock logo

About Alkermes (NASDAQ:ALKS) Stock

Alkermes Plc is a global biopharmaceutical company. It is engaged in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

ALKS Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Alkermes Testing Schizophrenia Drug
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
See More Headlines
Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

ALKS Company Calendar

Last Earnings
11/02/2022
Today
1/26/2023
Next Earnings (Estimated)
2/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALKS
CUSIP
G0176710
Employees
2,211
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$29.89
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+5.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
7 Analysts

Profitability

Net Income
$-48,170,000.00
Pretax Margin
-12.85%

Debt

Sales & Book Value

Annual Sales
$1.17 billion
Cash Flow
$0.75 per share
Book Value
$6.88 per share

Miscellaneous

Free Float
156,491,000
Market Cap
$4.68 billion
Optionable
Optionable
Beta
0.57

Social Links


Key Executives

  • Richard F. PopsRichard F. Pops
    Chairman & Chief Executive Officer
  • Blair C. Jackson
    Chief Operating Officer & Executive Vice President
  • Iain Michael BrownIain Michael Brown
    Chief Financial Officer & Senior Vice President
  • Thomas Harvey
    Chief Information Officer
  • Kanchan Relwani
    Senior Vice President-Medical Affairs













ALKS Stock - Frequently Asked Questions

Should I buy or sell Alkermes stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALKS shares.
View ALKS analyst ratings
or view top-rated stocks.

What is Alkermes' stock price forecast for 2023?

8 Wall Street research analysts have issued twelve-month price objectives for Alkermes' stock. Their ALKS share price forecasts range from $25.00 to $36.00. On average, they expect the company's stock price to reach $30.10 in the next twelve months. This suggests a possible upside of 5.6% from the stock's current price.
View analysts price targets for ALKS
or view top-rated stocks among Wall Street analysts.

How have ALKS shares performed in 2023?

Alkermes' stock was trading at $26.13 at the beginning of 2023. Since then, ALKS stock has increased by 9.1% and is now trading at $28.50.
View the best growth stocks for 2023 here
.

When is Alkermes' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our ALKS earnings forecast
.

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) issued its quarterly earnings data on Wednesday, November, 2nd. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The firm had revenue of $252.36 million for the quarter, compared to analyst estimates of $271.45 million. Alkermes had a negative trailing twelve-month return on equity of 1.10% and a negative net margin of 11.41%. The company's quarterly revenue was down 14.2% compared to the same quarter last year. During the same period last year, the company posted ($0.02) earnings per share.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of $0.15-$0.33 for the period, compared to the consensus earnings per share estimate of $0.20. The company issued revenue guidance of $1.07 billion-$1.12 billion, compared to the consensus revenue estimate of $1.10 billion.

What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Who are Alkermes' major shareholders?

Alkermes' stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.10%), Paradiem LLC (0.03%), Harbor Capital Advisors Inc. (0.02%), Strs Ohio (0.02%), Diversified Trust Co (0.02%) and Dupont Capital Management Corp (0.01%). Insiders that own company stock include Blair Curtis Jackson, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon.
View institutional ownership trends
.

How do I buy shares of Alkermes?

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $28.50.

How much money does Alkermes make?

Alkermes (NASDAQ:ALKS) has a market capitalization of $4.68 billion and generates $1.17 billion in revenue each year. The company earns $-48,170,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does Alkermes have?

The company employs 2,211 workers across the globe.

Does Alkermes have any subsidiaries?
The following companies are subsidiares of Alkermes: Rodin Therapeutics.
Read More
How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The official website for the company is www.alkermes.com. The company can be reached via phone at (531) 772-8000, via email at investor_relations@alkermes.com, or via fax at 781-890-0524.

This page (NASDAQ:ALKS) was last updated on 1/27/2023 by MarketBeat.com Staff